6
Registered trials
1
Recruiting
5
Unique sponsors
2
Unique IMPs
6
Commercial trials
Drug classes (ATC)
—
ATC code not specified
6
Mechanism of action (INN-stem analysis)
GLP-1 receptor agonist
1 substance
Unknown / small molecule
1 substance
Phase II:
2
Phase I:
1
Phase I (Other):
2
Other:
1
Phase II
2 trials-
Recruiting4moving Biotech CommercialLIRAGLUTIDE
-
EndedGlaxosmithkline Research & Development Limited CommercialGSK3858279
Phase I
1 trial-
EndedSanofi-Aventis Recherche & Developpement CommercialIMP not specified
Phase I (Other)
2 trials-
Ended4moving Biotech CommercialIMP not specified
-
EndedAmzell B.V. CommercialIMP not specified
Other
1 trial-
EndedHaleon CH SARL CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| 4moving Biotech | Commercial | 2 | Phase I (Other), Phase II | 1 |
| Sanofi-Aventis Recherche & Developpement | Commercial | 1 | Phase I | 0 |
| Haleon CH SARL | Commercial | 1 | Other | 0 |
| Amzell B.V. | Commercial | 1 | Phase I (Other) | 0 |
| Glaxosmithkline Research & Development Limited | Commercial | 1 | Phase II | 0 |
New trials by year
2023
2
2024
2
2025
2